Loncar Cancer Immunotherapy ETF (CNCR)
$28.74 0.00 (0.00%)
16:15 EDT CNCR Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 68.97M
PE Ratio -
Volume (Avg. Vol.)
Day's Range 28.74 - 28.74
52-Week Range 12.00 - 30.25
Dividend & Yield 0.35 (1.22%)
CNCR Stock Predictions, Articles, and Loncar Cancer Immunotherapy ETF News
- From InvestorPlace
- From the Web
Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.
Healthcare ETFs range from prosaic funds focusing on large-cap companies to funds offering access to fast-growing segments of the healthcare space. Here are 5 stellar options.
The tides have shifted, somewhat, since January and some of the best ETFs of February focus on unfamiliar spaces, while other ETFs maintained their general outperformance over the S&P 500.
These were the some of the best ETFs in January. Each outperformed the S&P 500 by at least 5% or more. Here's what investors need to know about each ETF.
While most of the stocks and ETFs have been surging over the past one month, there are some hidden gems that could surprise investors with big returns this Chri...
From Seeking Alpha
Health Care, and more specifically oncology, will continue to gain attention with the events on the calendar this week.The Sachs 20th Annual Biotech in Europe Forum runs from Monday to Thursday. Monday, morning, Amgen (NASDAQ:AMGN) will present results from a Phase 1 Study of AMG 160 for prostate cancer as part of the European Society of Medical Oncology Virtual Congress.And Tuesday morning, Merck, whose oncology division has outperformed competitors over the last few years, is hosting an Oncology Virtual IR Briefing as part of ESMO 2020, according to Seeking Alpha's Catalyst Watch.A wave of deals in the cancer-treatment space has sparked sharp rallies across biotech. The big trigger last week was Gilead Sciences (NASDAQ:GILD) agreeing to acquire Immunomedics (NASDAQ:IMMU) in a transaction that values Immunomedics at ~$21B, giving Gilead Trodelvy, used to treat certain forms of breast cancer and being evaluated for a number of other cancers.On Friday, Piper Sandler issued a list of biotechs that could be in the sights of acquirers for their oncology treatment.